Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$27.52 - $37.99 $3,687 - $5,090
-134 Reduced 0.79%
16,933 $547,000
Q1 2022

May 13, 2022

BUY
$30.71 - $45.71 $39,462 - $58,737
1,285 Added 8.14%
17,067 $565,000
Q4 2021

Mar 11, 2022

SELL
$37.06 - $47.11 $53,996 - $68,639
-1,457 Reduced 8.45%
15,782 $671,000
Q3 2021

Nov 10, 2021

BUY
$40.26 - $57.37 $694,042 - $989,001
17,239 New
17,239 $764,000
Q1 2020

May 13, 2020

SELL
$26.15 - $77.24 $268,900 - $794,258
-10,283 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$60.18 - $154.77 $618,830 - $1.59 Million
10,283 New
10,283 $742,000
Q3 2019

Nov 13, 2019

SELL
$140.29 - $189.96 $156,002 - $211,235
-1,112 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $175,529 - $203,596
1,112 New
1,112 $203,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Bokf, Na Portfolio

Follow Bokf, Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.